Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YAZBQ
ADC Name
RM-1995
Synonyms
RM 1995; RM-1995; RM1995
   Click to Show/Hide
Organization
Rakuten Medical, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Head and neck cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Interleukin-2 receptor subunit alpha (IL2RA)
  Antigen Info 
Payload Name
IRDye 700DX
  Payload Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05220748
Phase 1
A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05220748  Clinical Status Phase 1
Clinical Description A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.
References
Ref 1 A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma, NCT05220748